External referencing and pharmaceutical price negotiation
External referencing (ER) imposes a price cap for pharmaceuticals based on prices of identical products in foreign countries. Suppose a foreign country (F) negotiates prices with a pharmaceutical firm while a home country (H) can either negotiate independently or implement ER based on the foreign price. We show that country H always prefers ER if (i) it can condition ER on the drug being subsidized in the foreign country and (ii) copayments are higher in H than in F. H's preference isreinforced when the difference between country copayments is large and/or H's population is small. External referencing by H always harms F if (ii) holds, but less so if (i) holds.
|Date of creation:||2011|
|Publication status:||Published in Health Economics, Wiley, 2011, 20 (6), pp. 737-756. <10.1002/hec.1630>|
|Note:||View the original document on HAL open archive server: https://halshs.archives-ouvertes.fr/halshs-00303682|
|Contact details of provider:|| Web page: https://hal.archives-ouvertes.fr/|
References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Antonio Cabrales & Sergi Jiménez-Martín, 2007.
"The Determinants of Pricing in Pharmaceuticals: Are U.S. Prices Really Higher than Those of Canada?,"
UFAE and IAE Working Papers
697.07, Unitat de Fonaments de l'Anàlisi Econòmica (UAB) and Institut d'Anàlisi Econòmica (CSIC).
- Cabrales, Antonio & Jiménez-Martín, Sergi, 2007. "The determinants of pricing in pharmaceuticals : are U.S. prices really higher than those of Canada?," UC3M Working papers. Economics we074021, Universidad Carlos III de Madrid. Departamento de Economía.
- Antonio Cabrales & Sergi Jiménez-Martín, 2007. "The Determinants of Pricing in Pharmaceuticals: Are U.S. prices really higher than those of Canada?," Working Papers 304, Barcelona Graduate School of Economics.
- Antonio Cabrales & Sergi Jiménez-Martín, 2007. "The determinants of pricing in pharmaceuticals: Are U.S. prices really higher than those of Canada?," Economics Working Papers 1032, Department of Economics and Business, Universitat Pompeu Fabra.
- Danzon, Patricia M & Chao, Li-Wei, 2000. "Does Regulation Drive out Competition in Pharmaceutical Markets?," Journal of Law and Economics, University of Chicago Press, vol. 43(2), pages 311-357, October.
- Margaret K. Kyle, 2007. "Pharmaceutical Price Controls and Entry Strategies," The Review of Economics and Statistics, MIT Press, vol. 89(1), pages 88-99, February.
- Alexander Heuer & Malwina Mejer & Jennifer Neuhaus, 2007.
"The National Regulation of Pharmaceutical Markets and the Timing of New Drug Launches in Europe,"
Kiel Advanced Studies Working Papers
437, Kiel Institute for the World Economy.
- Heuer, Alexander & Mejer, Malwina & Neuhaus, Jennifer, 2007. "The national regulation of pharmaceutical markets and the timing of new drug launches in Europe," Kiel Advanced Studies Working Papers 437, Kiel Institute for the World Economy (IfW).
- Cooper, Thomas E. & Fries, Timothy L., 1991. "The most-favored-nation pricing policy and negotiated prices," International Journal of Industrial Organization, Elsevier, vol. 9(2), pages 209-223, June.
- Valérie Paris & Elizabeth Docteur, 2008. "Pharmaceutical Pricing and Reimbursement Policies in Germany," OECD Health Working Papers 39, OECD Publishing.
- Patricia Danzon, 1997. "Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 4(3), pages 301-322.
- Danzon, Patricia M. & Chao, Li-Wei, 2000. "Cross-national price differences for pharmaceuticals: how large, and why?," Journal of Health Economics, Elsevier, vol. 19(2), pages 159-195, March.
- Pecorino, Paul, 2002. "Should the US allow prescription drug reimports from Canada?," Journal of Health Economics, Elsevier, vol. 21(4), pages 699-708, July.
- Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2005.
"The impact of price regulation on the launch delay of new drugs-evidence from twenty-five major markets in the 1990s,"
John Wiley & Sons, Ltd., vol. 14(3), pages 269-292.
- Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2003. "The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s," NBER Working Papers 9874, National Bureau of Economic Research, Inc.
When requesting a correction, please mention this item's handle: RePEc:hal:journl:halshs-00303682. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (CCSD)
If references are entirely missing, you can add them using this form.